Livzon Pharmaceutical repurchases A shares across multiple dates

Livzon Pharmaceutical Group Inc. (HKEX:1513) announced a comprehensive series of A share repurchases in its latest Next Day Disclosure Return. The report details repurchases spanning from December 2024 to September 2025, with a notable transaction on September 15, 2025. On this date, the company repurchased 74,400 A shares on another stock exchange (Shenzhen Stock Exchange) at prices ranging from RMB 40.09 to RMB 40.62 per share, with an aggregate price paid of RMB 2,999,912. The closing balance of issued H shares as of September 15, 2025, remained at 299,807,117, with no change in treasury H shares.

The company's A share repurchases were ongoing throughout early 2025, with daily figures ranging from 48,600 to 561,400 shares. For example, on January 14, 2025, 561,400 A shares were repurchased at RMB 35.62, representing 0.0616% of existing issued A shares. Similarly, on February 12, 2025, 558,400 A shares were bought back at RMB 35.82, accounting for 0.06127% of issued shares.

Despite these ongoing repurchases, the total number of issued A shares (excluding treasury shares) remained at 604,293,313 as of September 15, 2025. This indicates that while repurchases were executed, the shares were not yet cancelled, consistent with the disclosure requirements. The report confirms that all repurchases were made in accordance with the Main Board Rules and relevant domestic rules.